Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | TGFB1 | P01137 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677060 | 0.88 | TGFBR1 (0.73) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL18041667 | 0.88 | TGFBR1 (0.73) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL18041636 | 0.88 | TGFBR1 (0.66) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL18042091 | 0.87 | TGFBR1 (0.71) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL29676950 | 0.87 | TGFBR1 (0.71) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL29676872 | 0.86 | TGFBR1 (0.67) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL18041669 | 0.86 | TGFBR1 (0.67) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL29676904 | 0.82 | TGFBR1 (0.92) | TGFBR1MAPK14 | |
| SCHEMBL18042120 | 0.82 | TGFBR1 (0.92) | TGFBR1MAPK14 | |
| SCHEMBL18041507 | 0.81 | TGFBR1 (0.73) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | claimed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | claimed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | claimed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | claimed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352360-B2 | TGF-beta inhibitors | Rigel Pharmaceuticals, hic. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-20200031832-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2020-01-30 | — | — | US | disclosed |
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-10287295-B2 | TGF-β inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-20180127426-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-05-10 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884868-B2 | TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-20160257690-A1 | TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352360-B2 | TGF-beta inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MAPK14 2266/4885RIPK2 1208/4885 |
| US-20200031832-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MAPK14 2266/4885RIPK2 1208/4885 |
| US-20180127426-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MAPK14 2266/4885RIPK2 1208/4885 |
| US-10287295-B2 | TGF-β inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MAPK14 2085/4885RIPK2 1089/4885 |
| US-20160257690-A1 | TGF-Beta Inhibitors | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MAPK14 2266/4885RIPK2 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.